잠시만 기다려 주세요. 로딩중입니다.

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus

Korean Journal of Internal Medicine 2020년 35권 1호 p.41 ~ 59
박은정 ( Park Eun-Jung ) - National Medical Center Department of Internal Medicine

김형진 ( Kim Hyung-Jin ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
정승민 ( Jung Seung-Min ) - Yonsei University College of Medicine Department of Internal Medicine
성윤경 ( Sung Yoon-Kyoung ) - Hanyang University Hospital for Rheumatic Diseases Department of Rheumatology
백한주 ( Baek Han-Joo ) - Gachon University Gil Medical Center Department of Internal Medicine
이지수 ( Lee Ji-Soo ) - Ewha Womans University School of Medicine Department of Internal Medicine

Abstract


Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert consensus for the use of bDMARDs drugs for inflammatory arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.

키워드

Expert consensus ; Biological disease-modifying antirheumatic drugs ; Inflammatory arthritis ; Arthritis, rheumatoid ; Spondylitis, ankylosing
원문 및 링크아웃 정보
  
등재저널 정보